A retrospective study involving 28 of the original trial participants (RRP-002) showed this number increasing to 86% at the end of the second 12 ... grade (Grade 1) treatment-emergent adverse effects ...
Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback